BioCentury | May 15, 2019
Finance

Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

...Roche’s few remaining clinical cardiometabolism assets, Sofinnova Investments has joined Sofinnova Partners, 5AM Ventures and CinRx...
...a $50 million series A and exclusive, worldwide rights to the pharma's aldosterone synthase inhibitor. CinRx...
...Teva. Pearce is CinRx and CinCor COO and was VP of R&D at Teva. Other CinRx...
Items per page:
1 - 1 of 1
BioCentury | May 15, 2019
Finance

Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

...Roche’s few remaining clinical cardiometabolism assets, Sofinnova Investments has joined Sofinnova Partners, 5AM Ventures and CinRx...
...a $50 million series A and exclusive, worldwide rights to the pharma's aldosterone synthase inhibitor. CinRx...
...Teva. Pearce is CinRx and CinCor COO and was VP of R&D at Teva. Other CinRx...
Items per page:
1 - 1 of 1